Clinical Trials in Ankara, Turkey (Türkiye)
869 recruiting
Showing 1–20 of 734 trials
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled301 locationsNCT06692738
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting
Phase 3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Essential Thrombocythemia
Merck Sharp & Dohme LLC300 enrolled167 locationsNCT06456346
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled205 locationsNCT05827081
Recruiting
Not Applicable
THE EFFECT OF GUİDED IMAGERY ON PREMENSTRUAL SYNDROME
NursingPremenstrual SyndromeGuided Imagery
Baskent University48 enrolled1 locationNCT07202650
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Primary Immune Deficiency
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled7 locationsNCT00246857
Recruiting
Phase 1Phase 2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled104 locationsNCT06996782
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC780 enrolled260 locationsNCT06312137
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled380 locationsNCT05920356
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 enrolled288 locationsNCT06585787
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled316 locationsNCT06103864
Recruiting
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled25 locationsNCT07279402
Recruiting
Phase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Merck Sharp & Dohme LLC96 enrolled32 locationsNCT06780085
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 2
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Lung Neoplasm
Merck Sharp & Dohme LLC144 enrolled40 locationsNCT06780098
Recruiting
Phase 2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Malignant Neoplasm
Merck Sharp & Dohme LLC130 enrolled21 locationsNCT07252739
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239